Research graph
References from Rational design, synthesis and structural characterization of peptides and peptidomimetics to target Hsp90/Cdc37 interaction for treating hepatocellular carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.21660
10.3322/caac.21660 · External reference
10.1038/s41572-020-00240-3
10.1038/s41572-020-00240-3 · External reference
Update on the diagnosis and treatment of hepatocellular carcinoma
2020 · External reference
Hepatocellular carcinoma
10.1056/nejmra1713263 · 2019 · External reference
Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability
10.1016/j.cld.2015.01.001 · 2015 · External reference
Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives
10.3748/wjg.v20.i2.333 · 2014 · External reference
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
10.1016/j.jhep.2021.11.030 · 2022 · External reference
Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma
2020 · External reference
Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts
10.18632/oncotarget.2171 · 2014 · External reference
10.1002/med.21807
10.1002/med.21807 · External reference
10.1016/s0092-8674(00)80928-9
10.1016/s0092-8674(00)80928-9 · External reference
10.1038/nature10317
10.1038/nature10317 · External reference
Cdc37 as a co-chaperone to Hsp90
10.1007/978-3-319-11731-7_5 · 2015 · External reference
Cdc37 as a Co-chaperone to Hsp90
10.1007/978-3-031-14740-1_5 · 2023 · External reference
The role of HSP90 molecular chaperones in hepatocellular carcinoma
10.1002/jcp.29776 · 2020 · External reference
10.1016/j.apsb.2020.11.015
10.1016/j.apsb.2020.11.015 · External reference
10.1158/1078-0432.ccr-11-1000
10.1158/1078-0432.ccr-11-1000 · External reference
10.1016/j.drudis.2016.11.003
10.1016/j.drudis.2016.11.003 · External reference
Unresolved reference
2021 · External reference
Peptidomimetics, a synthetic tool of drug discovery
10.1016/j.cbpa.2008.03.009 · 2008 · External reference
Peptidomimetic toolbox for drug discovery
10.1039/d0cs00102c · 2020 · External reference
Conversion of protein active regions into peptidomimetic therapeutic leads using backbone cyclization and cycloscan–how to do it yourself!
10.2174/1568026618666180518094322 · 2018 · External reference
Backbone-cyclized peptides: a critical review
10.2174/1568026618666180518092333 · 2018 · External reference
10.1080/17425247.2019.1676720
10.1080/17425247.2019.1676720 · External reference
Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application
10.3389/fphar.2020.00697 · 2020 · External reference
10.3390/cancers14225546
10.3390/cancers14225546 · External reference
10.1016/0092-8674(88)90263-2
10.1016/0092-8674(88)90263-2 · External reference
10.1093/nar/gky357
10.1093/nar/gky357 · External reference
Docking cyclic peptides formed by a disulfide bond through a hierarchical strategy
10.1093/bioinformatics/btac486 · 2022 · External reference
10.1038/s41586-021-03819-2
10.1038/s41586-021-03819-2 · External reference
CFSSP: Chou and Fasman secondary structure prediction server
2013 · External reference
Solid phase peptide synthesis I. The synthesis of a tetrapeptide
10.1021/ja00897a025 · 1963 · External reference
Backbone cyclization: a new method for conferring conformational constraint on peptides
10.1002/bip.360310619 · 1991 · External reference
Preparation of the very acid-sensitive Fmoc-Lys(Mtt)-OH. Application in the synthesis of side-chain to side-chain cyclic peptides and oligolysine cores suitable for the solid-phase assembly of MAPs and TASPs
10.1111/j.1399-3011.1995.tb01065.x · 1995 · External reference
Exploring biomolecular interaction between the molecular chaperone hsp90 and its client protein kinase cdc37 using field-effect biosensing technology
2022 · External reference
10.1016/j.bmc.2016.10.028
10.1016/j.bmc.2016.10.028 · External reference
10.1016/j.sbi.2016.12.009
10.1016/j.sbi.2016.12.009 · External reference
Unresolved reference
External reference
10.1107/s2059798322002261
10.1107/s2059798322002261 · External reference
Improving protein-peptide docking results via pose-clustering and rescoring with a combined knowledge-based and MM-GBSA scoring function
10.1021/acs.jcim.0c00058 · 2020 · External reference
Peptide inhibitors of protein-protein interactions
2010 · External reference
Cyclic peptides for protein-protein interaction targets: applications to human disease
10.1615/critreveukaryotgeneexpr.2016016525 · 2016 · External reference
Unresolved reference
External reference
10.1007/978-1-62703-673-3_17
10.1007/978-1-62703-673-3_17 · 2014 · External reference
10.1002/bip.360310511
10.1002/bip.360310511 · External reference
Suppressing the CDC 37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth
10.1111/liv.12651 · 2015 · External reference
Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma
10.1002/ijc.31963 · 2019 · External reference
The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis
10.4161/cbt.5.6.2907 · 2006 · External reference
Oncogenic properties of HIV-Tat in colorectal cancer cells
10.2174/157016207781023974 · 2007 · External reference
10.1016/s0002-9440(10)64156-9
10.1016/s0002-9440(10)64156-9 · External reference
Proliferative activity of extracellular HIV-1 Tat protein in human epithelial cells: expression profile of pathogenetically relevant genes
10.1186/1471-2180-5-20 · 2005 · External reference
Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties
10.1124/dmd.31.8.1035 · 2003 · External reference
10.1016/j.bioorg.2021.104867
10.1016/j.bioorg.2021.104867 · External reference
10.1186/1476-4598-13-150
10.1186/1476-4598-13-150 · External reference
10.1016/j.bmc.2018.02.021
10.1016/j.bmc.2018.02.021 · External reference
Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma
10.3892/ol.2017.5557 · 2017 · External reference
Requirement for a hsp90 chaperone-dependent MEK1/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes
10.1074/jbc.m200102200 · 2002 · External reference
